百令胶囊联合奥马珠单抗治疗儿童过敏性哮喘临床疗效及对呼吸道重塑的影响  

Curative Efficacy of Bailing Capsule(百令胶囊)in Combination with Omalizumab in Children with Allergic Asthma and Its Influences on Respiratory Tract Remodeling

作　　者：黄五乐 张华[1] 陈海丹[1] 吴慧莲[1] 王兰英 唐江利 HUANG Wule;ZHANG Hua;CHEN Haidan;WU Huilian;WANG Lanying;TANG Jiangli(Sanya Central Hospital,The Third People's Hospital of Hainan Province,Sanya 572000,Hainan,China)

机构地区：[1]三亚中心医院,海南省第三人民医院,海南三亚572000

出　　处：《中华中医药学刊》2022年第4期238-241,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：海南省卫生计生行业科研项目(1601032034A2001)。

摘　　要：目的探讨百令胶囊联合奥马珠单抗治疗儿童过敏性哮喘(allergic asthma,AS)临床疗效及呼吸道重塑的影响。方法选择2018年1月—2020年6月于医院接受治疗的110例AS儿童作为观察对象,随机分为对照组和观察组,每组55例。常规治疗基础上,对照组给予奥马珠单抗治疗,观察组给予百令胶囊联合奥马珠单抗治疗,疗程均为3个月。比较两组患儿临床疗效、哮喘症状评分、肺功能指标、血清过敏原特异性IgE抗体、过敏原特异性IgG4抗体(sIgG4)水平及呼吸道重塑指标水平。结果治疗后,与对照组相比,观察组患儿治疗总有效率提高[94.5%(52/55)vs 80.0%(44/53)],日间症状评分和夜间症状评分降低[(0.51±0.10)分vs(0.84±0.22)分],[(0.25±0.07)分vs(0.38±0.09)分],第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC等肺功能指标水平升高[(1.62±0.30)L vs(1.33±0.24)L,(1.93±0.37)L vs(1.74±0.23)L,86.01±2.94 vs 75.16±3.16],血清sIgE水平降低[(61.43±7.48)U/L vs(78.24±8.51)U/L],sIgG4水平升高[(69.30±8.12)U/L vs(55.27±7.28)U/L],基质金属蛋白酶9(MMP-9)、金属蛋白酶组织抑制因子1(TIMP-1)、转化生长因子β1(TGF-β1)等呼吸道重塑指标水平降低[(187.15±20.22)μg/L vs(218.92±24.30)μg/L,(140.89±15.23)μg/L vs(161.17±16.04)μg/L,(115.12±12.38)ng/L vs(124.70±14.21)ng/L],组间比较差异都有统计学意义(均P<0.05)。结论百令胶囊联合奥马珠单抗能够有效改善儿童AS临床症状,并且能够在一定程度上改善肺功能和呼吸道重塑,临床上值得应用。Objective To investigate the curative efficacy of Bailing Capsule(百令胶囊)in combination with omalizumab in children with allergic asthma(AS)and its influences on respiratory tract remodeling.Methods A total of 110 children with AS who received therapy in the hospital from January 2018 to June 2020 were selected as observational objects,and those patients were randomly divided into the control group and the observation group with 55 cases in each group.Besides conventional treatments,the control group was given omalizumab,while the observation group was Bailing Capsule in combination with omalizumab with a three-month course.Then,the curative efficacy,asthma symptom scores,indices of lung function,levels of serum allergen specific IgE antibody(sIgE),allegern specific IgG4 antibody(sIgG4)and levels of indices of respiratory tract remodeling were compared between the two groups.Results After treatment,in comparison with the control group,the observation group had higher total therapeutic efficacy ratio[94.5%(52/55)vs 80.0%(44/55)],lower daytime symptom score and night symptom score[(0.51±0.10)points vs(0.84±0.22)points,(0.25±0.07)points vs(0.38±0.09)points],increased levels of lung function indices of forced expiratory volume in the first second(FEV1)[(1.62±0.30)L vs(1.33±0.24)L],forced vital capacity(FVC)[(1.93±0.37)L vs(1.74±0.23)L],FEV1/FVC[(86.01±2.94)vs(75.16±3.16)],lower levels of serum sIgE[(61.43±7.48)U/L vs(78.24±8.51)U/L],higher level of sIgG4[(69.30±8.12)U/L vs(55.27±7.28)U/L],lower levels of respiratory tract remodeling indices of matrix metalloproteinase-9(MMP-9)[(187.15±20.22)μg/L vs(218.92±24.30)μg/L],tissue inhibitor of metalloproteinase-1(TIMP-1)[(140.89±15.23)μg/L vs(161.17±16.04)μg/L]and transforming growth factor beta-1(TGF-β1)[(115.12±12.38)ng/L vs(124.70±14.21)ng/L]with all statistical differences(all P<0.05).Conclusion Bailing Capsule in combination with omalizumab can improve symptoms in children with AS,and it can improve lung function and respiratory tract rem

关 键 词：百令胶囊 奥马珠单抗 儿童 过敏性哮喘 呼吸道重塑 基质金属蛋白酶9 金属蛋白酶组织抑制因子1 转化生长因子Β1 

分 类 号：R256.12[医药卫生—中医内科学]